Диагностика и лечение семейных форм рака щитовидной железы
Диссертация
В пользу большей агрессивности МРЩЖ у больных с мутациями в 634 кодоне по сравнению с мутациями в других кодонах говорят следующие данные: возраст больных на момент диагностики МРЩЖ при мутации в 634 кодоне был меньше по сравнению с пациентами с локализацией мутации в 620 кодоне: 23,4 и 41,3 лет. соответственно. А у больных с мутациями в кодонах 611, 791 и 804 заболевание диагностировано в ещё… Читать ещё >
Список литературы
- Бомаш Н.Ю. Морфологическая диагностика заболеваний щитовидной железы. М.:1. Медицина, 1981.- 176 С.
- Бржезовский В. Ж. Шенталь В.В. Любаев B.JI. и др. Современное состояние проблемыдиагностики и лечения медуллярного рака щитовидной железы. // Современная онкология 2002. — Т. 4. № 3. — С. 9−14.
- Валдина Е.А. Заболевания щитовидной железы / Краткое руководство, 2-е изд. С.-П6.2001.- С. 261−281.
- Гарькавцева Р Ф. Лиснянский И. Е. Клинико-генетические аспекты медуллярного ракащитовидной железы. //Вол р. онкол. 1989. № 6. — С.63−68.
- Ильин А. А. Румянцев П.О. Диагностика и лечение семейного медуллярного ракащитовидной железы. // Пробл. эндокринол. 2000. — № 4. -С.19−23.
- Ольшанский В. О. Демидов В.П., Воронецкий И. Б. Рак щитовидной железы.
- Комбинированное и комплексное лечение больных со злокачественными опухолями. Руководство для врачей // под ред. В. И. Чиссова. М. 1989. — С. 180−193.
- Пачес А.И., Пропп P.M. Рак щитовидной железы. М.: Центр внедрения достиженийнауки и техники «Москва». 1995. — 369 с.
- Agulid F., Vazquez G., Cadilla C.L. et al. Afro-American kindred with a new poin mutationin RET oncogene.// Proceedings of the 81я Annual Meeting of The Endocrine Society, San Diego, CA. 1999. — P.531. abstract P3−435.
- Angrist M., Bolk S., Haluska M. Germline mutations in glial cell-derived neurotrophic factor
- GDNF) and Ret in a Hirshprung’s disease patient. // Nat. Genet. 1996. — Vol. 14. — P. 341.
- Arts C.H. Bax N.M. Jansen M. et al. Prophylactic total thyroidectomy in childhood formultiple endocrine neoplasia type 2A: preliminary results. II Ned. Tijdschr. Geneeskd. 1999. — Vol. 143. № 2. — P. 98−104.
- Austoni M. Thyroid papillary carcinoma in identical twins. // Lancet 1988. — Vol. 1. № 8594, — P. 1115.
- Ball D.W. Baylin S.B., De Bustros A.C. Medullary thyroid carcinoma. Werner & Ingbar sthe thyroid: a fundamental and clinical text. Philadelphia, 2000. — P. 930−943.
- Bell В., Mazzaferri E.L. Familial adenomatous polyposis (Gardner's Syndrome) and thyroidcarcinoma. A case report and review of the literature. // Dig. Dis. Sci. 1993. — Vol. 38. № l.-P. 185−190.
- Berndt 1. Reuter M. Sailer B. et al. A new hot spot for mutations in the ret protooncogenecausing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. // J. Clin. Endocrinol. Metab. 1998. — Vol. 83, Ks 3. — P. 770−774.
- Bevan S., Pal Т. Greenberg C.R. et al. A comprehensive analysis of MNG1, TCOl, fPTC.
- PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCOl. // J. Clin. Endocrnol. Metab. 2001. — Vol. 86, № 8. — P. 3701−3704.
- Bignell G.R., Canzian F. Shayeghi M. et al. Familial nontoxic multinodular thyroid goiterlocus maps to chromosome 14q, but does not account for familial nonmedullary thyroid cancer. // Am. J. Genet. 1997. — Vol. 61, № 5. — P. 1123−1130.
- Boccia L.M., Green J.S., Joyce C. et al. Mutation of RET codon 768 is associated with the FMTC phenotype. // Clin. Genet. 1997. — Vol. 51, № 2. — P. 81−85.
- Bolino A., Schuffenecker I., Luo Y. et al. Ret mutations in exons 13 and 14 of FMTC patients. // Oncogene 1995. — Vol. 10, Kb 12. — P. 2415−2419.
- Borrego S" Eng C., Sanchez B. et al. Molecular analysis of the ret and GDNF genes in afamily with multiple endocrine neoplasia type 2A and Hirshprung disease. // J. Clin. Endocrinol. Metab. 1998. — Vol. 83. № 9. — P. 3361−3364.
- Brandi M.L., Gagel R.F., Angeli A. et al. Consensus. Guidelines for diagnosis and therapy of
- MEN type I and type 2. III. Clin. Endocrinol. Metab. 2001. — Vol. 86, № 12. — P. 56 585 671.
- Brierley J. Tsang R., Simpson WJ. et al. Medullary thyroid cancer: analyses of survival andprognostic factors and the role of radiation therapy in local control. // Thyroid -1996. -Vol. 6.-P. 305.
- Burgess J.R. Duffield A., Wilkinson S.J. et al. Two families with an autosomal dominantinheritance pattern for papillary carcinoma of the thyroid. II J. Clin. Endocrinol. Metab. -1997. -Vol. 82. № 2. P. 345−348.
- Canzian F., Amati P., Harach H.R. et al. A gene predisposing to familial thyroid tumors withcell oxyphilia maps to chromosome 19pl3.2. // Am. J. Hum. Genet. -1998. -Vol. 63, № 6. -P. 1743−1748.
- Caron P., Attie Т. Dav id D. et al. C618R mutation in exon 10 of the RET proto-oncogene ina kindred with multiple endocrine neoplasia type 2A and Hirshprung’s disease. // J. Clin. Endocrinol. Metab. 1996. — Vol. 81. № 7. — P. 2731−2733.
- Carson K.M., Bracamontes J. Jackson C.E. et al. Parent-of-origin effects in multipleendocrine neoplasia type 2B. // Am. J. Hum. Genet. 1994. — Vol. 55. № 6. — P. 10 761 082.
- Carson K.M., Dou S., Chi D., et al. Single missense mutation in the tyrosine kinase catalyticdomain of the ret protooncogene is associated with multiple endocrine neoplasia type 2B. // Proc. Natl. Acad. Sci. USA 1994. — Vol. 91. — P. 1579.
- Cetta F. Montalto G. et al. Germline mutations of the APC gene in patients with familialadenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. // J. Clin. Endocrinol. Metab. -2000. -Vol. 85. № 1. P. 286−292.
- Chanson P., Cadiot G., Murat A. Management of patients and subjects at risk for multipleendocrine neoplasia type 1: MEN-1. // Horm. Res. 1997. — Vol. 47. № 4. — P. 211−220.
- Colombo-Benkmann M. Bramswig J., Hoppner W. et al. Surgical strategy in a kindred witha rare RET protooncogene mutation of variable penetrance with regard to multiple endocrine neoplasia. // World. J. Surg. 2002. — Vol. 26, № 10. — P. 1286−1290.
- Cushman P.Jr. Familial endocrine tumors: report of two unrelated kindreds affected withpheochromocytoma, one also with multiple thyroid carcinomas. // Am. J. Med. 1962. -Vol. 32, № 3,-P. 352−360.
- Dahia P.L.M. Marsh D.J. Zheng Z. et al. Somatic deletions and mutations in the Cowdendisease gene, PTEN, in sporadic thyroid tumors. // Cancer Res. -1997. Vol. 57, № 21. -P. 4710−4713.
- Da Silva A.M., Maciel R.M., Da Silva M.R. et al. A novel germ-line point mutation in RETexon 8 (Gly (533)Cys) in a large kindred with familial medullary thyroid carcinoma. // J. Clin. Endocrinol. Metab. 2003. — Vol. 88, № 11. — P. 5438−5443.
- Donis-Keller H. Dou S., Chi D. et al. Mutations in the RET proto-oncogene are associatedwith MEN 2A and FMTC. // Hum. Mol. Genet. 1993. — Vol. 2. № 7. — P. 851−856.
- Douglas W. Ball. Stephen B. Baylin, Andree C. De Bustros. Medullary thyroid carcinoma. II
- Werner & Ingbar s the thyroid: a fundamental and clinical text. 2000. — P. 930−943.
- Dralle H. Gimm O. Simon D., et al. Prophylactic thyroidectomy in 75 children andadolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. // World J. Surg. 1998. — Vol. 22, № 7. — P. 744−750.
- Durbec P., Macos-Gutierres C.V., Kilkenny C., et al. GDNF signaling through the RETreceptor tyrosine kinase. // Nature 1996. — Vol. 381. — P. 789.
- Dunn J.M., Famdon J.R. Medullary thyroid carcinoma. // Br. J. Surg. 1993. — Vol. 80. № 1.- P. 6−9.
- Edery P. Lyonnet S., Mulligan L. et al. Mutations of the RET oncogene in Hirshprung’sdisease. // Nature 1994. — Vol. 367. № 6461. — P. 378−380.
- Eng C., Mulligan L.M., Smith D.P. Low frequency of germline mutations in the RET protooncogene in patients with apparently sporadic medullary thyroid carcinoma. // Clin. Endocrinol. 1995. — Vol. 43, № I.- P. 123−127.
- Fagin J.A. Familial nonmedullary thyroid carcinoma the case for genetic susceptibility. // J.
- Clin. Endocrinol. Metab. 1997. — Vol. 82. № 2. — P. 342−344.
- Fattoruso O., Quadro L. Libroa A. et al. A GTG to ATG novel point mutation at codon 804in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma. // Hum. Mut. 1998. — Suppl. I. — S. 167-S171.
- Feldman G.L., Edmonds M.W., Ainsworth P.J. et al. Variable expressivity of familialmedullary thyroid carcinoma (FMTC) due to a RET V804M (GTG—ATG) mutations. II Surgery 2000. — Vol. 128, № I. — P. 93−98.
- Fitze G. Schierz M. Bredow J., et al. Various penetrance of familial medullary thyroidcarcinoma in patients with RET protooncogene codon 790/791 germline mutations. // Ann Surg. 2002. — Vol. 236, № 5. — P.570−575.
- Frank-Raue K. Hoppner W., Buhr H. et al. Mutations of the RET protooncogene in Germanmultiple endocrine neoplasia families: relation between genotype and phenotype. // Exp. Clin. Endocrinol. Diabetes. 1997. — Vol. 105. Suppl. 4. — P. 76−78.
- Frich L., Glattre E. Akslen L.A. Familial occurrence of nonmedullary thyroid cancer: apopulation-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. // Cancer Epidemiol. Biomark. Prevent. -2001. Vol. 10. № 2.-P. 113−117.
- Freyer G., Dazord A. Schlumberger M. et al. Psychological impact of genetic testing infamilial medullary thyroid carcinoma: a multicentric pilot-evaluetion. // Ann. Oncol. -1999.-Vol. 10.-P. 87−95.
- Gagel R.F., Jackson C.E., Block M.A., et al. Age related probability of development ofhereditary medullary thyroid carcinoma. Hi. Pediatr. 1982. -Vol. 101. — P. 941.
- Gagel R.F., Tashjian A.H., Cummings Т., et al. The clinical outcome of prospectivescreening of multiple endocrine neoplasia type 2a. An 18-year experience. II N. Engl. J. Med. 1988.-Vol. 318.-P. 478.
- Gagel R.F., Levy M.L., Donovan D.T., et al. Multiple endocrine neoplasia type 2a associatedwith cutaneous lichen amyloidosis. И Ann. Intern. Med. 1989. — Vol. 111. — P. 802.
- Galanti M.R. Ekbom A., Grimelius L. et al. Parental cancer and risk of papillary andfollicular thyroid carcinoma. // Br. J. Cancer 1997. — Vol. 75, — Ks 3. P. 451 -456.
- Gimm O., Marsh D.J. Andrew S.D. Germline dinucleotide mutation in codon 883 of the retproto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. // J. Clin. Endocrinol. Metab. 1997. — Vol. 82, № 11. — P. 3902−3904.
- Goldgar D.E., Easton D.F., Cannon-Albright L.A. et al. Systematic population-basedassessment of cancer risk in first-degree relatives of cancer probands. II J. Natl. Cancer Inst- 1994.-Vol. 86, № 21.-P. 1600−1608.
- Grosfeld F.J.M. Lips C.J.M., Ten Kroode H.J.F. et al. Psychosocial consequences of DNAanalysis for MEN Type 2. II Oncology.-1996.-Vol. J0.-P. 141−146, 152.157.
- Grossman R.F., Tu S.H. Duh Q.Y. et al. Familial nonmedullary thyroid cancer. An emergingentity that warrants aggressive treatment. // Arch. Surg. 1995. — Vol. 130. № 8. — P. 892 897.
- Guillamondegui O.M., Mikhail R.A. The treatment of differentiated carcinoma of the thyroidgland. // Arch. Otolaryngol. 1983. — Vol. 109. — P. 743−745.
- Harach H.H., Williams G.T. Williams E.D. Familial adenomatous polyposis associatedthyroid carcinoma: a distinct type of follicular cell neoplasm. // Histopathology 1994. -Vol. 25, № 6.-P. 549−561.
- Hassett S., Costigan C. McDermott M. et al. Prophylactic thyroidectomy in the treatment ofthyroid medullary carcinoma. Age for surgery? // Eur. J. Pediatr. Surg. 2000. — Vol. 10. № 5. — P. 334−336.
- Hazard J. В. Hawk W.A. Crile G.Jr. Medullary (solid) carcinoma of the thyroid: aclinicopathologic entity. // J. Clin. Endocrinol. Metab. 1959. — Vol. 19. № 1. — P. 152 161.
- Hemminki K. Dong C. Familial relationships in thyroid cancer by histopathological type. II1.t. J. Cancer-2000. Vol. 85, № 16. — P. 201−205.
- Hidalgo M.A. Medrano M.E. Rodriguez S. et al. Presence of the 918 mutation in the RETproto-oncogene in a Mexican patient with multiple endocrine neoplasia 2B. II J. Exp. Clin. Res.- 1998.-Vol. 17, № 2.-P. 149−152.
- Hofstra R.M.W. Landsvater R.M. Ceccherini I. et al. A mutation in the ret proto-oncogeneassociated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. // Nature 1994. — Vol. 367. № 6461. — P. 375−376.
- Hofstra R.M.W. Fattosuro O. Quadro L. et al. A novel point mutation in the intracellulardomain of the ret protooncogene in the family whith medullary thyroid carcinoma. // J. Clin. Endocrinol. Metab. 1997. — Vol. 82. № 12. — P. 4176−4178.
- Hoie J., Heimdal K. Nesland J.M. et al. Prophylactic thyroidectomy in carriers of REToncogene mutation carriers. // Tidsskr. Nor. Laegeforen. 2000. — Vol. 120, № 27. P. -3249−3252.
- Hotz H.G., Runkel N. S., Frank-Raue K. et al. Prophylactic thyroidectomy in MEN IIA: does the calcitonin level correlate with tumor spread? // Langenbecks Arch. Surg. 1998. -Vol. 383.№ 2.-P. 170−173.
- Houlston R.S. Stratton M.R. Genetics of non-medullary thyroid cancer. // Q. J. Med. 1995.-Vol. 88. № 10.-P. 685−693.
- Howe J.R., Norton J.A., Wells S.A. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up.//Surgery 1993.-Vol. 114.-P. 1070.
- Huang S.-M. Kuo M.-S. Jin Y.-T. et al. Prophylactic total thyroidectomy in an 8-year-oldgirl mith multiple endocrine neoplasia type 2A. II J. Formos. Med. Assos. 2001. — Vol. 100, № 4. — P. 274−276.
- Ikeda I. Ishizaka Y. Tahira T. et al. Specific expression of the ret proto-oncogene in humanneuroblastoma cell lines.// Oncogene 1990. — Vol. 5. № 9. — P. 1291−1296.
- Ivanchuk S.M. Myers S.M. Eng C. et al. De novo mutations of GDNF ligand of theret/GDNF-alpha receptor complex in Hirshprung’s disease. // Hum. Mol. Genet. 1996. -Vol. 5.-P. 2023.
- Kahraman Т., de Groot J. W., Rouwe C., et al. Acceptable age for prophylactic surgery inchildren with multiple endocrine neoplasia type 2a. // Eur. J. Surg. Oncol. 2003. — Vol. 29, № 4. — P. 331−335.
- Kaserer K., Scheuba C., Neuhold N. et al. Recommendations for reporting С cell pathologyof the thyroid. // Wien Klin. Wochenschr. 2002. — Vol. 114, № 7. — P. 274−278.
- Kebebew E., Tresler P.A. Siperstein A.E. et al. Normal thyroid pathology in patientsundergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literature. //Thyroid.- 1999.-Vol. 9,№ 2.-P. 127−131.
- Kwok C.G. McDougall I.R. Familial differentiated carcinoma of the thyroid: report of fivepairs of siblings. // Thyroid 1995. — Vol. 5, № 5. — P. 395−397.
- Lallier M., St-Vil D., Giroux M. et al. Prophylactic thyroidectomy for medullary thyroidcarcinoma in gene carriers of MEN2 syndrome.// Semin. Pediatr. Surg. 1997. — Vol. 6. № 3. — P. 134−140.
- Learoyd D.L. Marsh D.J., Richardson A.-L. et al. Genetic testing for familial cancer.
- Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type2. //Arch. Surg.- 1997,-Vol. 132,№ 9.-P. 1022−1025.
- Lecube A. Hernandez C., Oriola J., et al. V804M RET mutation and familial medullaiythyroid carcinoma: report of a large family with expression of the disease only in the homozygous gene carriers.// Surgery. 2002. — Vol. 131. № 5. — P. 509−514.
- Leprat F., Alapetite C., Rosseli P. et al. Impaired DNA repair as assessed in patients withthyroid tumors after a history of radiation therapy: a preliminary study study. // Radiat. Oncol. Biol. Physics 1998. — Vol. 40, № 5. — P. 1019−1026.
- Lepra! F. Bonichon F. Guyot M. el al. Familial nonmedullary thyroid carcinoma: pathologyreview in 27 affected cases from 13 french families. // Clin. Endocrinol. 1999. — Vol. 50. Ks 5. — P. 589−594.
- Lesueur F" Stark M. Tocco T. et al. Genetic geterogenity in familial non-medullary thyroidcarcinoma: exclusion of linkage to RET. MNG 1 and TCO in 56 families. // J. Clin. Endocrinol. Metab. 1999. — Vol. 84, № 6. — P. 2157−2162.
- Lewinski A. Thyroid carcinoma: diagnostic and therapeutic approach- genetic backgroundreview). // Endocr. Regul. 2000. — Vol. 34. — P. 99−113.
- Liaw D" Marsh D.J., Li J. et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. // Nat. Genet. 1997. — Vol. 16. № 1. — P. 64−67.
- Lips C.J.M. Landsvater R.M. Hoppener J.W.M. et al. Clinical screening as compared with
- DNA analysis in families with multiple endocrine neoplasia type 2a. // N. Engl. J. Med. -1994.-Vol. 331, № 1. P. 828−835.
- Lips C.J.M. Hoppener J.W.M. Thijssen J.H.H. Medullary thyroid carcinoma: role of genetictesting and calcitonin measurement. // Ann. Clin. Biochem. 2001. — Vol. 38. — P. 168 179.
- Loh K.C. Familial nonmedullary thyroid carcinoma: a meta-review of case series. // Thyroid1997. Vol. 7. № 1. P. 107−113.
- Lombardo F. Baudin E., Chiefari E. et al. Familial medullary thyroid carcinoma: clinicalvariability and low aggressiveness associated with RET mutation at codon 804. // J. Clin. Endocrinol. Metab. 2002. — Vol. 87. № 4. — P. 1674−1680.
- Lote K., Andersen K., Nordal E. et al. Familial occurrence of papillary thyroid carcinoma. II
- Cancer 1980. — Vol. 46. № 5. — P. 1291−1297.
- Lupoli G., Cascone E., Alrotta F., et al. Treatment of advanced medullary thyroid carcinomawith a combination of recombinant interferon alpha-2b and octreotide. // Cancer 1996. -Vol. 78.-P. 1114.
- Lupoli G., Vitale G., Caraglia M. et al. Familial papillary thyroid microcarcinoma: a newclinical entity. II Lancet 1999. — Vol. 353, № 9153. — P. 637−639.
- Machens A., Gimm O., Hinze R. et al. Genotype-phenotype correlations in hereditarymedullaiy thyroid carcinoma: oncological features and biochemical properties. II J. Clin. Endocrinol. Metab. 2001.-Vol. 86. № 3.-P. 1104−1109.
- Malchoff C D. Malchoff D.M. Familial nonmedullary thyroid carcinoma. // Semin. Surg.
- Mallory S.B. Cowden syndrome (Multiple Hamartoma Syndrome). // Dermatol. Clinics -1995.-Vol. 13.№ l.-P.27−31.
- McKay J. Lesueur F. Jonard L. et al. Localization of a susceptibility for familial nonmedullary thyroid carcinoma to chromosome 2q21. // Am. J. Hum. Genet. 2001. -Vol 69.№ 2.-P. 440−446.
- McTieman A. Weiss N.S., Daling J.R. Incidence of thyroid cancer in women in relation to known or suspected risk factors for breast cancer. // Cancer Res. 1987. — Vol. 47. № 1. -P. 292−295.
- Marsh D.J. Mulligan L.M. Eng C. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. // Horm. Res. 1997. — Vol. 47. № 4. -P. 168-J 78.
- Mathew C.G.P., Chin K.S. Easton D.F. et. al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. // Nature 1987. — Vol. 328. № 6130. -P. 527−528.
- Melillo R.M. Barone M.V., Lupoli G. et al. Ret-mediated mitogenesis requires Src kinase activity. // Cancer Res. 1999. — Vol. 59. — P. 1120.
- Mendelsohn G. Wells S.A. Bayliln S.B. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. // Cancer 1984. — Vol. 54.-P. 657.
- Michiels F.M. Chappius. Caillou В. et al. Development of medullary thyroid carcinoma in transgenic mice expressing the RET proto-oncogene altered by a multiple endocrine neoplasia type 2A mutation. // PNAS 1997. — Vol. 94. — P.3330.
- Mulligan L.M. Kwok J.B.J. Healey C.S. et.al. Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A. // Nature 1993. — Vol. 363. № 6428. — P. 458−460.
- Mulligan L.M. Eng C. Healey C.S., et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2a and FMTC. // Nature Genet. 1994. — Vol. 3. № 6. — P. 70−74.
- Mulligan L.M., Ponder B.A.J. Genetic basis of endocrine neoplasia type 2. // J. Clin. Endocrinol. Metab. 1995. — Vol. 80, № 7. — P. 1989−1995.
- Murat A. Modigliani E., Conte-Devolx В., et al. Early therapeutic management of patients genetically predisposed to medullary thyroid cancer. // Ann. Chir. 1998. — Vol. 52, № 5. -P. 455−460.
- Niccoli-Sire P. Murat A., Rohmer V. et al. Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype-genotype relationship in a large series of patients. //1. Clin. Endocrinol. Metab. 2001. — Vol. 86, № 8. — P. 3746−3753.
- Niccoli-Sire P. Murat A. Rohmer V. et al. When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations? // Surgery 2003. — Vol. 134. № 6. — P. 1029−1036.
- Nilsson O., Tisell L.E., Jansson S. et al. Adrenal and extraadrenal pheochromocytomas in a family with germline RET V804L mutation. // JAMA 1999. — Vol. 281. № 17. — P 1587−1588.
- Orell S.R., Philips J. The Thyroid: fine-needle biopsy and cytological diagnosis of thyroid lesions. // In: Monographs in Clinical Cytology (Ed SR Orell). 1997. — Vol. 14.
- O’Riordain D.S., O’Brein Т. Weaver A.L. et al. Medullary thyroid carcinoma in multiple endocrine neoplasia type 2A and 2B. // Surgery 1994. — Vol. 116, № 6. — P. 1017−1023.
- Ozaki O. Ito K. Kobayashi K. et al. Familial occurrence of differentiated, non-medullary thyroid carcinoma. // World J. Surg. -1988. Vol. 12, № 4. — P. 565−571.
- Pachnis V. Mancoo В., Constantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. // Development 1993. — Vol. 119. — P. 1005.
- Petrusson S.R. Metastatic medullary thyroid carcinoma: complete response to combination chemotherapy with dacarbazine and 5-fIuorouracil. // Cancer-1988. Vol. 62. -P. 1899.
- Pigny P. Bauters C., Wemeau J.L. et al. A novel 9-base pair duplication in RET exon 8 familial medullary thyroid carcinoma. // J. Clin. Endocrinol. Metab. 1999. — Vol. 84, № 5.-P. 1700−1704.
- Ponder B.A.J. Coffey R., Gagel R.F. et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. // Lancet 1988. — Vol. 2. — P. 397.
- Rios A. Rodriguez J.M., lllana J. et al. Familial papillary carcinoma of the thyroid: report of three families. // Eur. J. Surg. 2001. — Vol. 167. № 5. — P. 339−343.
- Randolph G.W. Medullary carcinoma of the thyroid. // Cancer Control 2000. — Vol. 7. № 3. — P. 253−261.
- Rodriquez G.J., Balsalobre M.D. Pomares F., et al. // J. Am. Surg. 2002. — Vol. 195. № 2. -P. 159−166.
- Roher H.D., Simon D., Goretzki P.E., et al. Preventive radical surgery of C-cell carcinoma in MEN-1I syndrome based on genetic screening. // Chirurg. 1995. — Vol. 66, № 12. — P. 1196−1202.
- Romeo G" Ronshetto P. Luo Y. et al. Point mutation affecting the tyrosine kinase-domain of the RET proto-oncogene in Hirshprung’s disease. //Nature 1994. — Vol. 367. № 6461. -P. 377−378.
- Ron E., Kleinerman R.A., Boice J.D. et al. A population-based case-control study of thyroid cancer. //J. Natl. Cancer Inst. 1987. — Vol. 79, № I. — P. 1−12.
- Ron E., Kleinerman R.A., LiVolsi V.A. et al. Familial non-medullary thyroid cancer. // Oncology 1991. — Vol. 48. № 4. — P. 309−311.
- Russo D., Arturi F., Schlumberger M. et al. Activating mutations of the TSH receptor in differentiated thyroid carcinomas. //Oncogene- 1995.-Vol. 11. № 9.-P. 1907−1911.
- Saad M.F., Ordonez N.A. Rashid R.K., et at. Medullary carcinoma of the thyroid: a study of the clinical features and prognostic factors in 161 patients. // Medicine 1984. — Vol. 63.-P. 319−342.
- Saad M.F., Fritsche H.A. Samaan N.A. Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. // J. Clin. Endocrinol. Metab. 1984. — Vol. 58. — P. 889.
- Santoro M., Rosati R-, Grieco M. et al. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. // Oncogene 1990. -Vol. 5, № 10.-P. 1595−1598.
- Santoro М- Carlomagno F., Romano A. et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. U Science 1995. -Vol. 267, № 5196. — P. 381−383.
- Schlumberger M. Inheritable forms of thyroid carcinoma. // Thyroid International 2000. -№ 4. — P. 3−8.
- Schmid Т. Muhlig H.P. Spelsberg F. Preventive total thyroidectomy in children with MEN Ila syndrome// Chirurg. 1994. — Vol. 65. № 1. — P. 48−49.
- Schneider R. The human protooncogene ret- a communicative cadherin? // Trends Biochem. Sci.-1992.-Vol. 17.-P. 468.
- Schuffenecker 1. Ginet N. Goldar D. et al. Prevalence and parental origin of the novo RET mutation in MEN 2a and FMTC. // Am. J. Hum. Genet. -1997. Vol. 60. — P. 233−237.
- Seri M. Celli 1-, Bersos N. et al. A Cys 634 Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen planus. // Clin. Genet. 1997. -Vol. 51, № 2.-P. 86−90.
- Simpson N.E., Kidd K.K. Goodfellow P.J. et. al Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. // Nature 1988. — Vol. 328. № 5892. -P. 528−530.
- Skinner M.A. Wells S.A. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes. // Semin. Pediatr. Surg. 1997. — Vol. 6. № 3. — P. 134−140.
- Smith D.P. Houghton C. Ponder B.A.J. Germline mutation of RET codon 883 in two cases ofde novo MEN 2B. //Oncogene 1997. — Vol. 15. № до.- P. 1213−1217.
- Spinelli C. Puccini M. Bertocchini A., et al. Prophylactic total thyroidectomy in children and adolescents with genetic mutations in the RET-protooncogene. // Pediatr. Med. Chir. -2002. Vol. 24. № 1. — P. 53−57.
- Steiner A.L. Goodman A.D. Powers S.R. Study of kindred with pheochromocytoma. medullary thyroid carcinoma, hyperparathyroidism and Cushing’s disease: multiple endocrine neoplasia type 2. // Medicine (Baltimore) 1968. — Vol. 47. № 5. — P. 371 -409.
- Stoffer S.S. Van Dyke D.L. Bach J.V. et al. Familial papillary carcinoma of the thyroid. // Am. J. Med. Genet. 1986. — Vol. 25. № 4. — P. 775−782.
- Szinnai G. Meier C. Komminoth P. et al. Review of multiple endocrine neoplasia type 2 A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. // Pediatrics 2003. — Vol. Ill, № 2.- P. el32-el39.
- Takahashi M. Ritz J., Cooper G.M. Activation of a novel human transforming gene, ret. by DNA rearrangement. // Cell 1985. — Vol. 42, № 2. — P. 581−588.
- Takami H., Ozaki O., Ito K. Familial non-medullary thyroid cancer: an emerging entity that warrants aggressive treatment. II Arch. Surg. 1996. — Vol. 13 J, № 6. — P. 676.
- Tessitore A., Sinisi A.A., Pasquali D. et al. A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET proto-oncogene. II J. Clin. Endocrinol. Metab.- 1999.- Vol. 84. Ms 10.-P. 3522−3527.
- Thompson N.W. Nishiyama R.H., Harness J.K. Thyroid carcinoma: Current controversies. // Curr. Probl. Surg. 1978. — Vol. 15.-P. 1−67.
- Treanor J.J.S. Goodman L.C., de Sauvage F. et al. Characterization of a multicomponent receptor for GDNF. // Nature 1996. — Vol. 382. -P. 80.
- Tsuzuki Т. Takahashi M. Asai N. et al. Spatial and temporal expression of the ret-proto-oncogene product in embryonic, infant and adult rat tissues. // Oncogene 1995. — Vol. 10.-P. 191.
- Uchino S., Noguchi S., Kawamoto H. et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high reccurence rate in a large study population. // World J. Surg. 2002. Vol. 26. P. 897−902.
- Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. // Cell-1990.-Vol. 61.-P. 203.
- Vasen H.F.A., Van Der Feltz M. Raue F. et al. The natural course of multiple endocrine neoplasia type lib. A study of 18 cases. II Arch. Intern. Med. 1992. — Vol. 152. № 6. — P. 1250-J 252.
- Vassilopoulou-Sellin R. Palmer L. Taylor S. et al. Incidence of breast carcinoma in women with thyroid carcinoma. II Cancer 1999. — Vol. 85. № 3. — P. 696−705.
- Verga U. Fugazzola L. Cambiaghi S., et al. Frequent association between MEN 2A and cutaneous lichen amyloidosis. // Clin. Endocrinol. (Oxf). 2003. — Vol. 59. № 2. — P. 156 161.
- Wallin G., Bondesson A.G. Famebo L.O., et al. Hereditary thyroid cancer can be cured by prophylactic surgery. // Lakartidningen. 2001. — Vol. 98. № 25. — P. 3024−3028.
- Wells S.A.Jr. Chi D.D., Toshima K. et al. Predictive DNA testing in prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. // Ann. Surg. -1994. Vol. 220. № 3. — P. 237−247.
- Wells S.A.Jr. Skinner M.A. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. // Exp. Clin. Endocrinol. Diabetes. 1998. -Vol. 106. № 1. — P. 29−34.
- Wohllk N. Cote G.J. Bugalho M.M.J, et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. // J. Clin. Endocrinol. Metab. 1996. — Vol. 81, № 10.-P. 3740−3745.
- Wu L.T., Averbuch S.D. Chemotherapy of advanced thyroid cancer. II In: Cobin RH. Srota DK, eds. Malignant tumors of the thyroid. New York: Springer-Verlag. — 1992. — P. 204.
- Wu L.T., Averbuch S.D. Ball D.W. et al. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine and dacarbazine. // Cancer 1994. — Vol. 73. P. 432−436.
- ВОПРОСЫ ДЛЯ СКРИНИНГ-ОПРОСНИКА ПАЦИЕНТОВ С ПАТОЛОГИЕЙ ЩИТОВИДНОЙ ЖЕЛЕЗЫ1. Дата опроса.
- Фамилия, имя. отчество пациента / его родственника.
- Дата рождения (день / месяц / год).
- Адрес полный, телефон домашний / рабочий / соседей / родственников.
- Диагноз заключительный. pTNM для больных РЩЖ (из истории болезни или базы данных). Результаты последнего обследования (УЗИ. ТАБ. ТГ. МАТ. АТкТГ, СЕА. ТКТ) -в таблицу.
- Имеется ли у кого-либо из Ваших родственников заболевание ЩЖ?• диагноз клинический или ориентировочный (увеличение ЩЖ. узлы в ЩЖ)• год и результат последнего УЗИ ЩЖ * в таблицу• результаты ТАБ **, ТГ. МАТ. АТкТГ. СЕА. ТКТ (если есть) в таблицу
- При обнаружении узловых или кисгозных образований при УЗИ ЩЖ рекомендовать ТАБ (по месту жительства или в МРНЦ РАМН).скрининг-опросник пациентов с патологией щитовидной железы1. Дата опроса//2001. Ф.И.О.
- Дата рождения / /Тел (дом/раб)Моб.1. Адрес/1. ДиагнозрТ N М Дата1. Anamnesis vitae1. Сопутствующие заболев:1. Сведения о родственниках
- Обследование пациента и его родственников
- Степень родства УЗИ (дата) ТАБ (дата) ТГсыв. (N 0−50) ТКТ сыв. МАТ (N0-I2) АТкТГ (N 0−60)пациент